RheumNow Podcast with Special Guest Dr. Michael Weinblatt (9.22.2023) Save
Dr. Jack Cush is joined by Dr. Michael Weinblatt as they discuss this weeks news and journal reports, including difficult RA, HLA typing and abatacept responses and new regulatory decisions.
-
UCB has issued a press update on its pending application for the approval of their dual IL-17A/F inhibitor, Bimekizumab. A regulatory decision slated for 3rd quarter 2023 has been pushed back. The FDA is continuing its review of the BLA for bimekizumab https://bit.ly/3POHUB2
-
The EMA has approved an anti-IL-6/tocilizumab biosimilar, manufactured by Fresenius-Kabi, and called Tyenne. This is the 1st TCZ biosimilar, indicated for use in RA, Systemic JIA, poly-JIA, GCA, COVID-19 and CAR-T cell-induced cytokine release syndrome https://t.co/KGhOqmmjWe
-
Korean Biologics registry study of 2,321#RA pts Rx w/ b/tsDMARDs, 12% (271) were diagnosed with Difficult to Tx RA (D2TRA). D2TRA assoc w/ Lower age, longer Dz duration, lower pt globals, higher SDAI/RAPID3, Low RF+, less MTX, SSZ, LEF. https://t.co/nM3oH6NO4B
-
Japanese study of 106 RA pts starting ABA, TCZ or TNFi. Among the 37 starting ABA, 17 were + for HLA-DRB1*04:05 who were uniquely responsive (SDAI50=71%) compared to those without *04:05 haplotype (30%) (p=0.022) https://t.co/3tQz84vK1T
-
Tuesday Nite Rheumatology – Methotrexate Decisions featuring Drs. Miachael Weinblatt, Joel Kremer, Richar Conway and Grace Wright
-
Perspectives: Steroid Use in RA featuring Drs. Robert Landewe, Bryant England and Peter Nash
ADD THE FIRST COMMENT
Disclosures
The author has received compensation as an advisor or consultant on this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.